Law

/Tag:Law

IP Law Update Newsletter: December 2016

NEWSLETTER IP Law Update: December 2016 Volume 5, Issue 4   Intellectual Property Law Update We hope everyone is having an excellent holiday season and wish a Happy New Year to all of our friends and clients! To enhance your 2017 prospects, please consider these topics that are of great current significance. Need to use [...]

FisherBroyles Client Alert — Federal Judge in Texas Blocks Obama OT Law

Texas Judge Mazzant rules Congress intended duties, not wages, to determine eligibility for overtime and minimum wage. U.S. District Judge Amos Mazzant, in Sherman, Texas issued an emergency preliminary injunction on Tuesday, which stops overtime rules issued by the Obama administration from going into effect on December 1. The new overtime rules increase the automatic [...]

Client Alert – Former Valeant and Philidor Execs Charged in Fraud and Kickback Scheme

Little more than a year ago, the complex relationship between pharmaceutical giant Valeant and Philidor Rx Services, a Pennsylvania-based mail-order pharmacy, first drew the attention of government investigators and the press.  Now, two former executives—once from each company—have been charged by federal prosecutors with multiple counts of fraud and conspiracy. On November 17, 2016, ex-Valeant [...]

FisherBroyles Announces Major Expansion of its Intellectual Property Group

Eight Attorney Group Joins FisherBroyles’ Patent Team (Atlanta, GA — October 17, 2016) — FisherBroyles LLP announced today that eight attorneys from ALG Intellectual Property, LLC have joined the nation’s first and largest cloud-based law firm in a major expansion of the firm’s intellectual property group. ALG is a prominent intellectual property boutique based in [...]

PBMs in the Crosshairs

October 13, 2016 — As recently reported in the Wall Street Journal ("Drugmakers Point Finger at Middlemen for Rising Drug Prices"), prescription drug manufacturers are increasingly laying the blame for skyrocketing pharmaceutical prices on the so-called "middlemen" in the drug distribution life-cycle. Pharmaceutical executives, from Mylan CEO Heather Bresch to Pfizer Chief Executive Ian Read, are [...]